1. Home
  2. KLAR vs TGTX Comparison

KLAR vs TGTX Comparison

Compare KLAR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Klarna Group plc Ordinary Shares

KLAR

Klarna Group plc Ordinary Shares

HOLD

Current Price

$14.29

Market Cap

7.7B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.91

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLAR
TGTX
Founded
2005
1993
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
7.9B
IPO Year
2023
2008

Fundamental Metrics

Financial Performance
Metric
KLAR
TGTX
Price
$14.29
$54.91
Analyst Decision
Buy
Strong Buy
Analyst Count
16
5
Target Price
$38.00
$49.80
AVG Volume (30 Days)
6.3M
2.3M
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.17
Revenue
N/A
$2,785,000.00
Revenue This Year
$28.56
$49.08
Revenue Next Year
$19.93
$26.69
P/E Ratio
N/A
$323.71
Revenue Growth
N/A
N/A
52 Week Low
$12.06
$26.76
52 Week High
$47.48
$59.30

Technical Indicators

Market Signals
Indicator
KLAR
TGTX
Relative Strength Index (RSI) 33.67 57.45
Support Level $12.77 $51.22
Resistance Level $15.30 $58.08
Average True Range (ATR) 0.78 2.25
MACD -0.49 0.68
Stochastic Oscillator 9.78 67.83

Price Performance

Historical Comparison
KLAR
TGTX

About KLAR Klarna Group plc Ordinary Shares

Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: